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BACKGROUND: Insulin-like growth factor-I (IGF-I) has been shown to increase kidney growth, glomerular filtration rate, and renal
function.
METHODS: In the prospective Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) study of 29133 Finnish male smokers
aged 50–69 years, serum concentrations of IGF were measured in samples collected in 1985–1988. A total of 100 men with kidney
cancer diagnosed X5 years after blood collection through 1997 were compared with a subcohort of 400 men; logistic regression
models were used to estimate the risk of developing kidney cancer.
RESULTS: Men with IGF-I levels 4113ngml
 1 were 59% less likely to develop kidney cancer than men with levels p113ngml
 1
(odds ratio¼0.41; 95% confidence interval¼0.23–0.75). The IGF binding protein-3 (IGFBP-3) levels did not alter the association.
No association was observed between IGFBP-3, or molar ratio of IGF-I/IGFBP-3, and kidney cancer.
CONCLUSIONS: Low serum IGF-I levels in this cohort of older middle-aged male smokers are associated with increased kidney cancer
risk, independent of IGFBP-3.
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Kidney cancer, comprised of cases including both clear cell renal
cell carcinoma (RCC) and transitional cell carcinoma of the renal
pelvis, is the seventh and ninth most common cancer in men and
women, respectively, in the United States, with an estimated 58000
diagnoses and 13000 deaths in 2009 (American Cancer Society,
2009). Incidence is highest in those ages 50–70 years, and almost
twice as high in men as in women (Parkin et al, 2002). Two
established risk factors include smoking, with smokers being twice
as likely as nonsmokers to develop RCC and four times as likely to
develop cancer of the renal pelvis, and obesity (Chow et al, 2000;
Murai and Oya, 2004; McLaughlin et al, 2006; Pischon et al, 2006;
World Cancer Research Fund/American Institute for Cancer
Research, 2007). Increased bioavailable insulin-like growth
factor-I (IGF-I) levels may be one mechanism through which
obesity increases kidney cancer risk.
Insulin-like growth factor-I is a single-chain polypeptide,
secreted primarily by the liver in response to growth hormone
that serves important functions in normal growth, development,
and metabolism. It acts through endocrine, paracrine, and
autocrine mechanisms (LeRoith et al, 1992; Jones and Clemmons,
1995) to influence cell proliferation, differentiation, and apoptosis
in a variety of tissues (Pollak, 2000; Moschos and Mantzoros, 2002;
Juul, 2003). Higher serum levels have been associated with
increased risk of cancers of the prostate, colon, breast, and lung
(Chan et al, 1998; Hankinson et al, 1998; Ma et al, 1999; Yu et al,
1999; Wakai et al, 2002; Renehan et al, 2004; Rowlands et al, 2009).
The impact of IGF-I is influenced by IGF binding protein-3
(IGFBP-3), the most abundant high-affinity BP in circulation that
binds 475% of all IGF-I (Ferry et al, 1999; Cheung et al, 2004). In
the kidney, IGF-I has been shown to increase growth of the
microvasculature and the glomerular filtration rate, and adminis-
tration of IGF-I has been shown to increase renal function and
been proposed as a possible therapeutic agent in chronic renal
failure (Hirschberg and Adler, 1998). We conducted a case–cohort
study nested within the Alpha-Tocopherol, Beta-Carotene Cancer
Prevention (ATBC) study of Finnish male smokers to examine the
prospective relation of IGF-I and IGFBP-3 to risk of kidney cancer.
MATERIALS AND METHODS
The ATBC study is a randomized intervention trial that tested
whether supplementation with a-tocopherol, b-carotene (or both)
reduced the incidence of lung and other cancers. Details of the
ATBC study have been described (The ATBC Cancer Prevention
Study Group, 1994). Briefly, the study cohort consisted of 29133
eligible men residing in southwestern Finland, aged 50–69 years,
who smoked at least five cigarettes per day at study entry, with
participants being enrolled between 1985 and 1988. Men with a
history of cancer were not eligible to participate. The institutional
review boards of the National Public Health Institute in Finland
and the US National Cancer Institute approved the study protocol,
and written informed consent was obtained from the participants
before study enrolment.
At study entry, investigators administered questionnaires that
collected information on lifestyle behaviours and medical history.
Height and weight were measured using standard methods, and
body mass index (kgm
 2) was calculated. Fasting blood samples
were collected at the baseline visit and stored frozen at  701C until
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IGF-I and IGFBP-3 were measured in serum by enzyme-linked
immunosorbent assays (Diagnostic Systems Laboratory Inc,
Houston, TX, USA). The intra-assay coefficient of variation (CV)
was 5.2% for IGF-I and 4.2% for IGFBP-3; the inter-assay CV was
4.6 and 6.2%, respectively.
Diagnosis of kidney cancer was defined by the International
Classification of Diseases, 9th Revision (ICD-9 codes 189.0, 189.1,
and 189.2). Incidence of cancer through the end of 1997 was
ascertained through linkage with the Finnish Cancer Registry and
study-based reviews; medical records were reviewed by study
physicians to confirm cancer diagnosis. During up to 13 years of
follow-up, 100 incident cases of kidney cancer were randomly
selected from 121 cases diagnosed at least 5 years after the baseline
blood collection (i.e., in order to both conserve limited serum
resources and reduce reverse causality). To serve as a subcohort
comparison group, we randomly selected 400 men from the full
ATBC study cohort who were in active study follow-up for at least
5 years and also cancer free at that time. Hence, all the participants
in this study were alive and without evidence of cancer during the
first 5 years of follow-up.
Statistical analysis
The IGF-I to IGFBP-3 molar ratio was calculated as a measure
of bioavailability using the following conversion: 1ngml
 1
IGF-I ¼0.130nmoll
 1 and 1ngml
 1 IGFBP-3 ¼0.036nmoll
 1.
Quartiles of IGF concentrations were calculated based on the
distribution in the comparison group.
Descriptive statistics were calculated for baseline characteristics
of participants by kidney cancer status; differences between cases
and the comparison group were determined using Studentized
t-tests, Wilcoxon rank sum, and w
2-statistics for group compa-
risons of means, medians, and proportions, respectively. General
linear models were used to evaluate the association of potential
confounders with quartiles of IGF concentrations among the
comparison group. Unconditional logistic regression models
were used to estimate the association between quintiles of IGF
concentrations and risk of kidney cancer. In addition to evaluating
cross-product terms along with the main effects in the models,
associations were examined stratified by number of cigarettes
smoked per day (p20 vs 420) and history of hypertension. Trend
tests were calculated by including the median of each quartile
of serum IGF concentrations as a continuous variable in addition
to the covariates in the final multivariable models. Statistical
significance was based on two-sided P-values of o0.05. All
statistical analyses were carried out using SAS version 9.1
(SAS Institute Inc., Cary, NC, USA).
RESULTS
Baseline characteristics of the study participants according to
kidney cancer status are presented in Table 1. Men who developed
kidney cancer were slightly older (mean age, 58 vs 56 years;
P¼0.03), had lower consumption of alcohol, and smoked more
cigarettes daily. In addition, a history of hypertension was
significantly more common among men with kidney cancer (28.0
vs 18.5%, P¼0.04), known to be more common in those who are
older, overweight, or heavier smokers. Most characteristics did not
differ considerably across quartiles of IGF-I and IGFBP-3 (Table 2),
Table 1 Baseline characteristics (mean±s.d. or n (%)) by kidney cancer
cases and comparison group
Characteristic
Cases
(n¼100)
Comparison
group (n¼400) P
Age at randomization (years) 58±55 6 ±5 0.03
a
Height (cm) 174.6±5.7 173.8±6.0 0.24
Weight (kg) 82.6±12.5 80.4±13.2 0.14
BMI (kgm
 2) 27.1±3.7 26.6±3.9 0.28
Alcohol intake (gday
 1) 7.5 (0–250) 11.4 (0–179) 0.05
b
Smoking history
Cigarettes per day 22.7±0.8 20.5±8.4 0.04
a
Years smoked 35.6±0.7 34.8±8.5 0.04
a
Physical activity – leisure 0.73
Light 43 (43.0) 172 (42.9) —
Moderate 53 (53.0) 204 (51.1) —
Heavy 4 (4.0) 24 (6.1) —
Medical history
Diabetes 8 (8.0) 28 (7.0) 0.73
Hypertension 28 (28.0) 74 (18.5) 0.04
c
IGF-I (ngml
 1) 133 (34–291) 139 (45–348) 0.51
IGFBP-3 (ngml
 1) 2412 (952–4174) 2334 (714–4211) 0.60
IGF-I/IGFBP-3 molar ratio 0.21 (0.10–0.39) 0.22 (0.08–0.46) 0.11
Abbreviations: BMI¼body mass index; IGFBP-3¼insulin-like growth factor binding
protein-3; IGF-I¼insulin-like growth factor-I. Medians (ranges) are reported for
measures of insulin-like growth factors and alcohol intake. Diabetes¼history of
diabetes and/or fasting glucose X126mg per 100ml; hypertension¼history of
hypertension, elevated blood pressure.
aSignificant based on Studentized t-test.
bSignificant based on Wilcoxon rank sum.
cSignificant based on w
2.
Table 2 Characteristics by quartiles of IGF-I and IGFBP-3 among comparison group
IGF-I IGFBP-3
Characteristic Q1 Q2 Q3 Q4 P Q1 Q2 Q3 Q4 P
Age (years) 57.0 57.2 55.9 55.4 0.02 57.8 57.1 55.6 55.0 o0.01
Height (cm) 172.7 173.4 173.4 175.7 o0.01 172.2 174.0 173.8 175.3 o0.01
Weight (kg) 77.1 81.4 79.8 83.5 0.01 76.2 79.0 81.4 85.2 o0.01
BMI (kgm
 2) 25.8 27.0 26.5 27.0 0.09 25.7 26.1 26.9 27.7 o0.01
Alcohol intake (gday
 1) 19.9 12.2 9.3 12.2 0.42 10.3 14.6 10.0 12.2 0.96
Cigarettes per day 21.2 20.5 20.2 20.0 0.74 21.0 19.7 20.7 20.5 0.73
Years smoked 36.2 35.2 33.8 34.2 0.19 37.3 36.0 32.8 33.3 o0.01
Leisure physical activity (moderate+/light) 52.0 56.0 59.0 61.0 0.60 47.0 59.0 63.0 59.0 0.12
Diabetes (yes/no) 11.0 8.0 5.0 4.0 0.20 10.0 7.0 4.0 7.0 0.43
Hypertension (yes/no) 12.0 19.0 20.0 23.0 0.23 13.0 17.0 20.0 24.0 0.23
IGF-I (ngml
 1) 93.6 125.3 153.6 207.2 o0.01 106.6 129.0 155.3 188.4 o0.01
IGFBP-3 (ngml
 1) 1830 2178 2424 2972 o0.01 1694 2166 2546 3197 o0.01
Abbreviations: BMI¼body mass index; IGFBP-3¼insulin-like growth factor binding protein-3; IGF-I¼insulin-like growth factor-I. Medians are reported for measures of IGF and
alcohol intake. P-values based on analysis of variance, Kruskal–Wallis, and w
2-tests.
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heavier. Also, higher IGFBP-3 was more common in younger men
and those with fewer years of smoking, the latter possibly being
explained by its correlation with age. The trial supplementation
group assignment was not associated with IGF measures (P40.30,
each) or kidney cancer (P¼0.85) (data not shown).
As shown in Figure 1, the multivariable-adjusted odds ratios
(ORs) and 95% confidence interval (CIs) for kidney cancer
for increasing quartiles of IGF-I were 0.40 (0.20–0.79), 0.39
(0.19–0.81), and 0.40 (0.18–0.90) compared with the low-quartile
reference category. The overall association between IGF-I and
kidney cancer was statistically significant (Type III Analysis of
Effects, P¼0.03), however, there was no evidence of a dose-risk
trend. With regard to the IGFBP-3, the ORs suggest a decreased
risk for men in the lowest quartile and a modest trend; however,
only men in the third quartile were at significantly increased
risk compared with men in the lowest quartile (OR¼2.46;
95% CI¼1.15–5.27), and the trend test was not significant. For
IGF-I/IGFBP-3 molar ratio, overall the association between molar
ratio and kidney cancer was not statistically significant (Type III
Analysis of Effects, P¼0.39), nor were any of the individual
quartiles when compared with the reference category (Figure 1).
As the ORs for individual IGF-I quartiles 2 through 4 did not
materially differ from one another and were in the same direction,
we re-examined the associations for quartiles 2–4 combined.
An inverse association between IGF-I serum levels and kidney
cancer risk was statistically significant (Type III Analysis of Effects,
Po0.01) when comparing the top three quartiles combined to the
lowest quartile. Men with IGF-I levels 4113ngml
 1 were 59% less
likely to develop kidney cancer than men with IGF-I levels
p113ngml
 1 (OR¼0.41; 95% CI¼0.23–0.75). Exclusion of renal
pelvic cancers (n¼11) yielded similar results (data not shown). No
significant interactions were observed between the IGF measures
and number of cigarettes smoked daily (p20 vs 420) (P40.60,
both IGF-I and IGFBP-3) or history of hypertension (P40.25, both
IGF-I and IGFBP-3).
DISCUSSION
In this cohort of Finnish male smokers, we found a significant
inverse association between serum IGF-I concentrations and risk
of kidney cancer and a nonstatistically significant positive
association for IGFBP-3. Men with IGF-I levels 4113ngml
 1
were 59% less likely to develop kidney cancer than men with lower
levels. To our knowledge, this study is the first population-based,
epidemiologic investigation to examine the association between
serum IGF and kidney cancer.
Our findings are not in accord with experimental studies, in
which IGF has been shown to have promoting effects on renal
carcinogenesis. In vitro studies (Cheung et al, 2004) demonstrated
that IGF-I stimulated growth of cultured human metastatic
RCC cells; however, only weak effects were observed for IGF-I
and IGFBP-3 in the nonmetastatic RCC cells. Furthermore, an
immunohistochemistry analysis of tissue from 180 RCC patients
showed that IGF-I expression was strong in clear cell, but not
papillary, tumours, indicating differential expression across
histologies (Schips et al, 2004). Mixed findings have been reported
for IGF-IR, with one study demonstrating increased expression
and another failing to detect any expression in human RCC tissue
(Ramp et al, 1997).
In a clinical study of 256 consecutive RCC patients investigating
the relation between serum IGF-I and disease progression and
survival (Rasmuson et al, 2004), researchers found that male and
female patients with serum IGF levels greater than the median
value were 38% less likely to die of RCC compared with patients
with serum levels below the median (hazard ratio¼0.62, 95%
CI¼0.41–0.95) and that IGF-I levels were inversely proportional
to tumour stage and grade. Unfortunately, the small number of
cases and the nonroutine ascertainment of tumour characteristics
preclude our ability to examine these associations in the ATBC
study. The increased risk of kidney cancer associated with lower
IGF-I levels we observed in ATBC is consistent with two recent
investigations from the ATBC study that found an inverse
association of IGF-I levels and incidence of glioma (Lonn et al,
2007) and liver cancer (unpublished). How low IGF-I levels might
lead to increased risk of kidney cancer, as compared with other
cancers thought to be positively associated (e.g., breast, colorectal,
prostate), is not apparent from a biological perspective. IGF-I
contributes to the regulation of glomerular filtration and kidney
growth, and its administration has been shown to improve renal
10.0
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0.1
Cases: 35 19 21 25
Q1 (ref.)
0.40 0.39 0.40
Q2 Q3 Q4
IGF-I
P value = 0.03
P value = 0.14
10.0
1.0
0.1
Cases: 22 22 31 25
Q1 (ref.)
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P value = 0.39
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Figure 1 Multivariable-adjusted odds ratios for quartiles of IGF-I,
IGFBP-3, and IGF-I/IGFBP-3 molar ratio. Adjusted for age, weight, height,
cigarettes per day, and hypertension. IGF-I and IGFBP-3 were simulta-
neously adjusted for in their respective models. P-values for overall effect.
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patients with chronic renal failure (Hirschberg and Adler, 1998).
Impedance in glomerular filtration rate and renal plasma flow may
make the kidney more susceptible to carcinogenesis. IGF-I and
IGFBP-3 are involved in an array of physiological and pathophy-
siological processes that could also impact risk.
Among the inherent strengths of our study is the ability to
measure pre-diagnostic levels of IGFs, thereby supporting the
temporal criterion for causality. Participants were followed for up
to 12.7 years and all participants who were diagnosed with cancer
within the first 5 years after the baseline blood collection were
excluded, thus minimizing the possible influence of subclinical
disease. Furthermore, as the kidneys are not a major source for
production of IGFs, it is unlikely that the observed association
reflects an effect of the disease. Because baseline information
on factors known (or suspected) to modify the risk of kidney
cancer existed in the parent study, we were able to elucidate the
independent effects of IGF by multivariable adjustment.
A limitation of our study is that all participants were male
smokers; therefore, the findings may not be generalizable to other
populations, including women and nonsmokers, and the possible
effects of smoking status (never, former, current smoker) on the
observed associations cannot be examined. A potential concern is
the higher proportion of men with hypertension among cases
(28%). It may be that consistently elevated blood pressure
promotes kidney cancer by causing damage to kidney tubules
that may amplify the effect of IGF-I. Although we did not detect
a significant interaction between hypertension and the IGF
measures, and IGF concentrations were not significantly elevated
among men reporting hypertension (after adjustment for age and
BMI), the lack of statistical significance is likely contributed to by
the small number of cases in this study.
In conclusion, our findings provide support for a relation
between low IGF-I and kidney cancer risk, but require confirma-
tion in larger, ethnically diverse populations that include women
and nonsmokers.
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